Year: 2024

Webcast and Conference Call To be Held Monday, December 23, 2024, 8:30 am ET NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its fiscal year ended September 30, 2024, on Monday, December 23, 2024. Management will host a conference call on Monday, December 23, at 8:30 am ET to review financial results and provide an update on the execution of the Company’s growth strategy. Following management’s remarks, there will be a...

CALGARY, Alberta, Dec. 16, 2024 (GLOBE NEWSWIRE) — Tornado Global Hydrovacs Ltd. (“Tornado”, the “Company” or “we”) (TSX-V: TGH; OTCQX: TGHLF) is pleased to announce that the Company is rebranding itself to align with its broader strategic vision and expansion into the United States. Name Change Effective December 18, 2024 (the “Effective Date”), the Company’s name will change to Tornado Infrastructure Equipment Ltd. (the “Name Change”). As of the Effective Date of the Name Change, the Company’s new CUSIP will be 891082109 and new ISIN will be CA8910821096. The Name Change reflects the Company’s commitment to diversifying its product lines to meet the increasing needs of the infrastructure market and better communicate the Company’s capacity to provide comprehensive, turn-key solutions and ability to serve its customers effectively. Because...

Largest Single Order in Vicon 57-year History Highlights Technology Strength and Growth Strategy Hauppauge, NY, Dec. 16, 2024 (GLOBE NEWSWIRE) — Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, announced today that its Vicon Industries subsidiary has received a record breaking $10.4 million order for a state government corrections facility in the mid-Atlantic region. This significant order will expand the customer’s Valerus surveillance security system with additional hardware, including enhanced storage infrastructure. The order, the largest in Vicon’s 57-year history, underscores Vicon’s commitment to delivering state-of-the-art surveillance solutions and is expected to be fulfilled in the Company’s second fiscal quarter of 2025, fully within Cemtrex’s fiscal year. Specific...

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer. “Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.” Ms. Hensley most recently served as senior vice president, assistant general counsel and chief compliance officer at Seres Therapeutics,...

VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to announce North Target drill hole results of the 2024 season from its wholly owned Thorn Project located in NW British Columbia, Canada. The Thorn Project is an underexplored copper-gold porphyry district with many large scale exploration target areas identified. HighlightsBrixton Metals’ maiden drill program at the North Target has intercepted a Mo-Cu porphyry system with mineralization starting from surface consisting of:Multiple generations of porphyry-style quartz and quartz-anhydrite veins hosting molybdenite, pyrite, and chalcopyrite accompanied by potassic alteration halosAnomalous copper and molybdenum within multi-kilometer scale alteration zones of phyllic,...

Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced positive topline results from a real-world evidence (RWE) study supporting ANX005 as a potential treatment...

Patrick SwindlePatrick Swindle, President and Chief Operating Officer, CoreCivic, Inc.BRENTWOOD, Tenn., Dec. 16, 2024 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that CoreCivic’s Board of Directors (the “Board”) has appointed Patrick Swindle, who currently serves as CoreCivic’s Executive Vice President and Chief Operating Officer, to President and Chief Operating Officer, effective January 1, 2025. Damon T. Hininger, who currently serves as CoreCivic’s Chief Executive Officer and President, will continue serving as CoreCivic’s Chief Executive Officer and as a member of the Board. Mr. Hininger commented, “Patrick is an exceptional leader with a wide set of skills and talents and over the years has developed an in-depth knowledge of...